Xu Liang 1 , Linhui Zhang 1 , inyu Gui 1, Lijun Di 1, Huiping Li 1 , Guohong Song. Real-world study of palbociclib combined withendocrine therapy for patients with metastatic breastcancer A comparison of subseguent treatmentpatterns and HER2 expression analvsis. .,Cancer,2024 Apr 15;130(S8):1476-1487

Xu Liang1,Xinyu Gui1, Ying Yan1, Lijun Di1, Xiaoran Liu1, Huiping Li*,?,1, Guohong Song（通讯作者）Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.,Oncologist,2024 Feb 2;29(2):e198-e205

Ruyan Zhang?, Yifei Chen?, Xiaoran Liu, Xinyu Gui, Anjie Zhu,Hanfang Jiang, Bin Shao, Xu Liang, Ying Yan, Jiayang Zhang,Guohong Song* and Huiping Li*.Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting,Front. Oncol,16 June 2023

Huiping Li1,; Guohong Song1#（共同第一作者）Qiaoxia Zhou2 · Ran Ran, et al. Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer.,Breast Cancer Research and Treatment,2021; 8.2021; 189(3):725-736

Xu Liang, Ying Yan, Guohong Song（共同通讯作者）A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view.,Transl Breast Cancer Res,2022;3:32

Wen Lei, Huiping Li?, Guohong Song?( Corresponding author), Ruyan Zhang, Ran Ran, Ying Yan, Lijun Di, Hanfang Jiang.Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.,Journal of Cancer.,2020; 11(22): 6612-6622.

宋国红,李惠平,邸立军,严颖,姜晗昉,徐玲,万冬桂,李瑛,王墨培,肖宇,张如艳,冉然,王环.真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性研究[J].),北京大学学报(医学版),2020,6(12)1-19.

陈祎霏，严 颖，姜晗昉，邸立军，宋国红（通讯作者），李惠平。促性腺激素释放激素激动剂对绝经前激素受体阳性乳腺癌患者去势效果分析——真实世界研究,,军事医学,2021;45 (5) :373-379.

«乳腺癌病例精解», 主编, 科学技术文献出版社, 2020.5

曲妥珠单抗（皮下制剂）、吡咯替尼联合达尔西利和内分泌治疗用于HR+/HER2+晚期乳腺癌的全国多中心单臂探索性临床研究, 课题负责人, 2024.7.21～2027.7.21, 北京融合医学发展基金会

基于原子力谱和纳米红外光谱的肿瘤源性细胞外囊泡研究, 参加者, 2020.1.10～2023.12.10, 国家自然科学基金面上项目

依维莫司联合内分泌治疗（芳香化酶抑制剂或氟维司群）对HR阳性、HER2阴性晚期乳腺癌CDK4/6抑制剂治疗进展患者的有效性及安全性研究，2023年01月至2024年12月，, 课题负责人, 2023.1.20～2024.12.20, 吴阶平基金

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2025	肿瘤内科学	硕士	专业学位	临床技能训练与研究	全国统考